相关实验视频
Updated: May 13, 2025

07:08
The Lambda Select cII Mutation Detection System
Published on: April 26, 2018
7.8K
鉴定致变性,MOA和剂量响应分析
Christopher A Bates1, Lynne T Haber2, Rita Schoeny3
1H.B. Fuller.
概括
一个新的癌症风险评估框架通过考虑基因突变,剂量指标和暴露数据来评估饮食中的致癌物. 这种方法为明智的管理决策提供了对癌症风险的细微了解.
科学领域:
- 毒理学 毒理学 毒理学
- 风险评估 风险评估
- 分子生物学分子生物学
背景情况:
- 传统的癌症风险评估通常依赖于动物瘤发生率数据.
- 评估致癌物质需要了解它们的作用机制 (MOA) 和剂量反应关系.
- 饮食中的致癌物质对准确的人类健康风险评估构成了复杂的挑战.
研究的目的:
- 测试一种新的癌症风险评估框架,使用三种已知的动物致癌物:烯胺,阿弗拉托克素B1和β-米尔.
- 与传统方法相比,评估框架能够提供更细致的癌症风险评估的能力.
- 评估与通过饮食接触这些特定化学物质相关的人类癌症风险.
主要方法:
- 该框架整合了基因突变分析作为早期癌症事件指标.
- 它认为剂量指标适合该化学品的MOA.
- 暴露数据和剂量反应评估用于确定癌症关注程度.
主要成果:
- 阿弗拉托克素B1的致癌性涉及基因突变作为早期事件,支持线性低剂量推断.
- 烯胺和β-米尔的致癌性数据表明剂量值方法.
- 对烯胺和β-米尔的饮食暴露模式表明癌症风险较低.
结论:
- 开发的框架为癌症风险评估提供了更精细的方法.
- 它通过结合MOA和暴露模式,更好地了解癌症风险.
- 该框架支持对食致癌物更明智的风险管理决策.
相关概念视频
Mutagenicity and Carcinogenicity
1.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.1K
In-vitro Mutagenesis
13.6K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
13.6K
Dose-Response Relationship: Overview
2.8K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
2.8K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
106
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
106

